Akebia Therapeutics, Inc. (AKBA) Institutional Ownership

Ownership Summary

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is held by 165 institutional investors per 13F filings through December 2025.

• Collectively, these holders controlled 43.1% of Akebia Therapeutics's outstanding shares in December 2025, down from 46.1% in September 2025.
• They decreased total shares held in Akebia Therapeutics by -0.88% from the prior quarter, while the number of investors in AKBA increased 35.25% year over year.
• Of these 165 funds, 85 grew their exposure to Akebia Therapeutics, 48 cut back, and 32 maintained positions.
• Combined, these investors held 118.36Mn shares in AKBA for December 2025, down by 1.05Mn shares quarter on quarter, and up 48.0Mn shares year over year.
• BlackRock, Inc. is the top holder of Akebia Therapeutics as of December 31, 2025, with 18.69Mn shares representing 6.81% of outstanding stock.
• The biggest buyers of Akebia Therapeutics for the quarter ending December 2025 included VANGUARD CAPITAL MANAGEMENT LLC (11.17Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (2.22Mn), VANGUARD FIDUCIARY TRUST CO (1.78Mn), TWO SIGMA INVESTMENTS, LP (1.21Mn), AQR CAPITAL MANAGEMENT LLC (1.15Mn).
• The biggest sellers of Akebia Therapeutics for the quarter ending December 2025 included Goldman Sachs Group Inc (5.81Mn), CITADEL ADVISORS LLC (3.28Mn), State Street Corp (2.07Mn), RENAISSANCE TECHNOLOGIES LLC (1.76Mn), ACADIAN ASSET MANAGEMENT LLC (822.68K).
• Business Quant data shows the 10 biggest positions in Akebia Therapeutics as of December 2025 are held by BlackRock, Inc. (18.69Mn), State Street Corp (11.61Mn), VANGUARD CAPITAL MANAGEMENT LLC (11.17Mn), GEODE CAPITAL MANAGEMENT, LLC (6.45Mn), Goldman Sachs Group Inc (3.6Mn), Citigroup Inc (2.85Mn), Bank Of America Corp /De/ (2.76Mn), Qube Research & Technologies Ltd (2.4Mn), MILLENNIUM MANAGEMENT LLC (2.38Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (2.22Mn).